Happiness and social appearance anxiety in overweight young girls.

OBJECTIVE: This research was conducted to determine the relationship between social appearance anxiety and happiness in overweight young girls. SUBJECTS AND METHODS: This is a correlational descriptive study and the study sample included 343 overweight young female students from a university in eastern Turkey. A Personal Information Form, the Oxford Happiness Questionnaire-Short Form (OHQ-SF), and the Social Appearance Anxiety Scale (SAAS) were used for data collection. Descriptive statistics (percentage, mean, standard deviation), independent-samples t-test, analysis of variance, and correlation and regression analyses were used in data analysis. RESULTS: The mean age of the participants was 21.55 ± 3.03 years. About a third of the participants (30.6%) was composed by year 3 university students, 60.6% had an income level equal to their expenditure level, and 50.7% was residing in the city center. The OHQ-SF mean total score of the participants was 17.03 ± 5.86, and the SAAS mean total score was 43.36 ± 17.07. There was a moderate negative correlation between the mean scores of the OHQ-SF and the SAAS (r: -.547, p<0.001). Social appearance anxiety explained 30% of happiness in young girls participating in the study (ß: -.547, p<0.001). CONCLUSIONS: Happiness in young girls was effective on social appearance anxiety. Health professionals may also evaluate the level of happiness in the care and counseling services they provide to young girls during extraordinary circumstances such as the COVID-19 pandemic.

EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

Background: The efficacy of ravulizumab (intravenous [IV] formulation;administered every 8 weeks) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) has been demonstrated in several randomized trials (NCT02946463, NCT03056040, NCT03406507). In study 303 (NCT03748823), subcutaneous (SC) ravulizumab, administered weekly via an on-body delivery system, showed pharmacokinetic non-inferiority to IV ravulizumab in adult patients with PNH who were clinically stable on prior IV eculizumab treatment. Here, we report results from the first 1 year of SC treatment, starting at day 15 for patients who continued SC ravulizumab during the extension period (SC/SC) and day 71 for patients who switched from IV ravulizumab to SC ravulizumab (IV/SC). Aims: To evaluate the efficacy, treatment administration satisfaction and safety of SC ravulizumab through the first 1 year (day 351) of treatment in adult patients with PNH previously treated with eculizumab. Methods: Patients (≥ 18 years) with clinically stable PNH (lactate dehydrogenase [LDH] levels ≤ 1.5 × upper limit of normal [246 U/L]) and ≥ 3 months prior eculizumab treatment were enrolled in the study, which consisted of a screening period (day-1 to day-30), a 10-week randomized treatment period and an extension period of up to 172 weeks. During the randomized treatment period, patients were assigned (2:1 ratio) to receive either SC ravulizumab or IV ravulizumab;all patients received SC ravulizumab during the extension period. Efficacy endpoints included: change in LDH from baseline;incidence of breakthrough hemolysis;transfusion avoidance;and stabilized hemoglobin (avoidance of a ≥ 2 g/dL decrease in hemoglobin in the absence of transfusion). Treatment administration satisfaction was assessed via the Treatment Administration Satisfaction Questionnaire (TASQ), which has been validated in a PNH population. Safety, including adverse events (AEs), serious AEs (SAEs) and adverse device effects (ADEs), were also assessed up to the 1-year data cut-off. Results: In total, 128 patients received SC ravulizumab (SC/SC: n = 84;IV/SC: n = 44;mean [range] duration of SC treatment: 486.4 [37-709] days). Efficacy endpoints (SC/SC and IV/SC) remained stable over time through 1 year of SC ravulizumab treatment. Mean (standard deviation [SD]) percentage change in LDH from baseline to SC day 351 was 0.9% (20.5%). Breakthrough hemolysis events were infrequent: 5/128 patients (3.9%);no event was considered free C5-related. Transfusion avoidance was maintained in 83.6% of patients during SC treatment, and 79.7% achieved stabilized hemoglobin. Improvement in total TASQ score with SC ravulizumab (compared with baseline IV eculizumab) was apparent at the first post-SC treatment assessment (SC day 29) and maintained until data cut-off (Figure). The most common AEs (reported by ≥ 10% of patients, excluding ADEs related to device product issues) during SC treatment were headache (14.1%, all grade ≤ 2), COVID-19 (14.1%, one death) and pyrexia (10.9%);injection site reaction (4.7%) was the most common non-device related ADE. Treatment-emergent SAEs were experienced by 21.1% of patients through to data cut-off. Although many patients had ≥ 1 device issue ADE, full SC dose administration was achieved in 99.9% of attempts. ADE incidence decreased over time. Image: Summary/Conclusion: The SC method of administration provides an additional treatment option for patients with PNH receiving ravulizumab therapy. Patients may be switched from IV eculizumab or IV ravulizumab to SC ravulizumab without loss of efficacy.

The effect of university students’ perceptions of coronavirus anxiety on their level of socialization through sports

Study Objectives: This study aimed to examine the effects of university students’ perceptions of coronavirus anxiety on their level of socialization through sports. For this purpose, a total of 284 students, 205 male, 79 female, students studying at Mehmet Akif Ersoy University Faculty of Sports Sciences in the fall semester of the 2021-2022 academic year constitute the universe of the study. Among the students who constitute the population of the study, 114 students are studying in the Department of Physical Education and Sports Teaching, 8 in the Department of Sports Management, and 162 in the Department of Coaching Education. Methods: In the analysis of the study data, descriptive statistics such as mean, standard deviation, frequency, and percentage values were examined. Test of normality was examined first to determine whether parametric analyzes will be performed. Results: When the socialization levels of university students through sports were evaluated according to age groups, the level of socialization through sports of students in the 21-22 age group is significantly higher than the level of socialization through sports of the students in the 18-22 age group. It was determined that the levels of socialization through sports of the students studying in the coaching education department were significantly higher than the levels of socialization through sports of the students studying in the physical education and sports teaching department. Conclusion: In the correlation analysis, it was determined that there was a very weak negative correlation between the coronavirus anxiety and the sports and socialization.

A Cross-Sectional Study Investigating Mental Health Among Turkish Citizens During The COVID-19 Pandemic: The Importance of Perceived Social Support

Objective: The COVID-19 pandemic has increased the stress burden and related mental problems all over the world. The changes in social life required the examination of psychosocial variables in this period. This study aimed to investigate the levels of depression, anxiety, stress, poor sleep quality, and insomnia in Turkish society during the COVID-19 pandemic and examine the relationship between those and perceived social support. Methods: A total number of 1032 participants completed the online survey form consisting of sociodemographic data form, Multidimensional Scale of Perceived Social Support (MSPSS), Depression Anxiety Stress Scale-42 (DASS-42), Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI). A series of univariate and multivariate analyses were used to examine the association of perceived social support with depression, anxiety, stress, poor sleep quality, and insomnia. All tests of associations were carried out at a level of significance of <0.05 and a 95% confidence interval. Results: The proportion of the participants having low perceived social support was 11.2% (n=116), having moderate perceived social support was 27.6% (n=285), having high perceived social support was 61.2 % (n=632). Based on the cut-off values of the relevant scales, the rates of depression, anxiety, high stress, poor sleep quality, and insomnia were found to be 54.6%, 47.6%, 47.8%, 58.8%, and 42.2%, respectively. According to multivariate linear regression analyses, MSPSS scores significantly predicted DASS-depression (p<0.001), DASS-anxiety (p<0.001), DASS-stress (p<0.001), PSQI (p<0.001), and ISI scores (p<0.001). Besides, being aged 18-30, female sex, being unemployed, COVID-19 history, having a chronic disease, and current psychiatric treatment were associated with at least one of the symptom clusters of depression, anxiety, stress, poor sleep quality, and insomnia. Conclusion: The current study indicated that depression, anxiety, high stress, poor sleep quality, and insomnia were prevalent among the participants at the end of the first year of the pandemic. Besides, perceived social support predicts mental health in a favorable way. In this respect, perceived social support is a potential target for individual and community-based therapeutic interventions.

ADHERENCE to PROPHYLAXIS in MODERATE and SEVERE HAEMOPHILIA in A PANDEMIC LIFE SETTING

Introduction: Compliance to a prophylactic therapy provides decreased bleeding rates in patients with haemophilia. During covid 19 pandemic, reaching and managing the health system has been a challenge for all over the world. It seems that these days are more difficult for hemophilia patients. The health policy recommend to need to avoid face to face communications if not certainly necessary for patients. It has become hard to admit out-patient clinics routinely and also emergency room for bleeding attacks for hemophilia patients. Aim: To evaluate adherence in adult patients with severe or moderate haemophilia under prophylactic treatment in a pandemic-life setting. Methods: This cross-sectional study, including 104 adult hemophilia patients receiving factor therapy in 5 Turkish centres. Participants rated the relevance of the single items of the VERITAS-PRO on a 5-point Likert scale and answered various questionnaires to assess their therapy beliefs. Also some information on their inspection file like this annual bleeding rate, age, diagnosis, target joint, etc. were used for study. Self-perceived adherence was compared versus the VERITAS-Pro questionnaire. The relationship between adherence rate and treatment, clinical and demographic characteristics was investigated. VERITAS pro questionnaire contains a total of six subscales with four items. Lower scores reflect higher adherence. Results: 104 adult patients with severe (72,5 %) and moderate (27,5 %) haemophilia receiving prophylaxis were eligible for the study. Median age was 38 years (range 18-69). Mean adherence rate of VERITAS pro total score was 38,16±12,06 (min: 22- max: 98) and this showed that 92 % of participant had treatment adherence. There was lower, significant and negative correlation between self-perceived degree of adherence and score of VERITAS -pro (Rho: -0,391 p<0,01). 43% of patients infused factor concantrate when he was suitable. Only 43,7 % of patient infused the factor concentrate at right time, in other words when starting the day. Discussion/Conclusion: VERITAS-Pro which is a valid and reliable instrument confirmed with different data from different countries. We have previously reported its Turkish version and our new multicenter study showed its usefullnes during pandemic of covid 19.